Similar articles for PMID: 22968692

Year	Number of Results
2008	1
2010	3
2011	14
2012	23
2013	14
2014	20
2015	13
2016	18
2017	12
2018	1
2019	3
2021	5
2022	3
2024	0

1

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Morales La Madrid A, Campbell N, Smith S, Cohn SL, Salgia R. Morales La Madrid A, et al. Target Oncol. 2012 Sep;7(3):199-210. doi: 10.1007/s11523-012-0227-8. Epub 2012 Sep 12. Target Oncol. 2012. PMID: 22968692 Review.

2

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F. Gridelli C, et al. Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Cancer Treat Rev. 2014. PMID: 23931927 Review.

3

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Mossé YP, et al. Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16. Lancet Oncol. 2013. PMID: 23598171 Free PMC article. Clinical Trial.

4

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Ou SH. Ou SH. Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23. Drug Des Devel Ther. 2011. PMID: 22162641 Free PMC article. Review.

5

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI. Rodig SJ, et al. Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Curr Opin Investig Drugs. 2010. PMID: 21154129 Review.

6

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Doebele RC, et al. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10. Clin Cancer Res. 2012. PMID: 22235099 Free PMC article.

7

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.

Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C. Casaluce F, et al. Curr Clin Pharmacol. 2016;11(2):77-87. doi: 10.2174/1574884711666160502124134. Curr Clin Pharmacol. 2016. PMID: 27138017 Review.

8

Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.

Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ. Hembrough T, et al. Clin Chem. 2016 Jan;62(1):252-61. doi: 10.1373/clinchem.2015.245860. Epub 2015 Nov 19. Clin Chem. 2016. PMID: 26585927 Free PMC article.

9

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.

Croegaert K, Kolesar JM. Croegaert K, et al. Am J Health Syst Pharm. 2015 Sep 1;72(17):1456-62. doi: 10.2146/ajhp140836. Am J Health Syst Pharm. 2015. PMID: 26294238 Review.

10

Targeting anaplastic lymphoma kinase in lung cancer.

Shaw AT, Solomon B. Shaw AT, et al. Clin Cancer Res. 2011 Apr 15;17(8):2081-6. doi: 10.1158/1078-0432.CCR-10-1591. Epub 2011 Feb 2. Clin Cancer Res. 2011. PMID: 21288922 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

120 results

Results by year